113173
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
纳米复合材料在克服肝细胞癌索拉非尼耐药性治疗中的应用
Authors Liu J, Zhou S, Wei Y, Du J , Jia F, Dong W, Cao Y, Shi Z, Mu H, Chen L, Yu S
Received 19 April 2025
Accepted for publication 26 August 2025
Published 26 December 2025 Volume 2025:20 Pages 15723—15767
DOI https://doi.org/10.2147/IJN.S535455
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Prof. Dr. RDK Misra
Jie Liu,1,* Shizhao Zhou,1,* Yingying Wei,2,3 Jinglei Du,2 Fan Jia,4 Wenhui Dong,1 Yangyi Cao,5 Zhenyang Shi,1 Hongkai Mu,1 Lin Chen,6 Shiping Yu2
1Medical Imaging Department, Shanxi Medical University, Taiyuan, Shanxi, 030001, People’s Republic of China; 2Department of Interventional Therapy, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, 030013, People’s Republic of China; 3Affiliated Cancer Hospital, Shanxi Medical University, Taiyuan, Shanxi, 030001, People’s Republic of China; 4Department of Oncology and Vascular Intervention, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030001, People’s Republic of China; 5Academy of Medical Sciences, Shanxi Medical University, Taiyuan, Shanxi, 030001, People’s Republic of China; 6Key Laboratory of Interface Science and Engineering in Advanced Materials, Ministry of Education, Taiyuan University of Technology, Taiyuan, Shanxi, 030024, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Lin Chen, Email chenlin01@tyut.edu.cn Shiping Yu, Email yushiping6@126.com
Abstract: The emergence of drug resistance is the major obstacle to the clinical application of sorafenib (SOR), which often leads to disease progression, recurrence, and even death in hepatocellular carcinoma (HCC) patients. Nanocomposite-mediated drug delivery enhances targeting precision and therapeutic utilization efficiency. Nanocomposites constructed by nanoparticles (NPs) and various therapeutic components have emerged as effective approaches to enhance HCC therapeutic efficacy. Designing based on the mechanisms underlying SOR resistance, specially engineered nanocomposites can be designed to overcome SOR resistance. This review aims to highlight the advantages of nanocomposites in overcoming HCC SOR resistance. First, the various SOR resistance mechanisms that have been identified so far are briefly outlined. Second, the construction methods and characteristics of nanocomposites designed to overcome SOR resistance are summarized and categorized according to different types of NPs. Subsequently, the roles and therapeutic effects of nanocomposites in SOR-resistant HCC are analyzed, primarily including remodeling the tumor microenvironment (TME), restoring normal epigenetic regulation, improving drug metabolism, and inhibiting abnormally activated signaling molecules and pathways. Finally, the advantages and disadvantages of nanocomposites used to reverse drug resistance are discussed, and their development direction in future research is prospected, which provide new approaches for developing advanced nanocomposites to overcome SOR resistance.
Keywords: nanocomposites, nanoparticles, nanomedicine, hepatocellular carcinoma, sorafenib, drug resistance, drug delivery, combination therapies
1Medical Imaging Department, Shanxi Medical University, Taiyuan, Shanxi, 030001, People’s Republic of China; 2Department of Interventional Therapy, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, 030013, People’s Republic of China; 3Affiliated Cancer Hospital, Shanxi Medical University, Taiyuan, Shanxi, 030001, People’s Republic of China; 4Department of Oncology and Vascular Intervention, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030001, People’s Republic of China; 5Academy of Medical Sciences, Shanxi Medical University, Taiyuan, Shanxi, 030001, People’s Republic of China; 6Key Laboratory of Interface Science and Engineering in Advanced Materials, Ministry of Education, Taiyuan University of Technology, Taiyuan, Shanxi, 030024, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Lin Chen, Email chenlin01@tyut.edu.cn Shiping Yu, Email yushiping6@126.com
Abstract: The emergence of drug resistance is the major obstacle to the clinical application of sorafenib (SOR), which often leads to disease progression, recurrence, and even death in hepatocellular carcinoma (HCC) patients. Nanocomposite-mediated drug delivery enhances targeting precision and therapeutic utilization efficiency. Nanocomposites constructed by nanoparticles (NPs) and various therapeutic components have emerged as effective approaches to enhance HCC therapeutic efficacy. Designing based on the mechanisms underlying SOR resistance, specially engineered nanocomposites can be designed to overcome SOR resistance. This review aims to highlight the advantages of nanocomposites in overcoming HCC SOR resistance. First, the various SOR resistance mechanisms that have been identified so far are briefly outlined. Second, the construction methods and characteristics of nanocomposites designed to overcome SOR resistance are summarized and categorized according to different types of NPs. Subsequently, the roles and therapeutic effects of nanocomposites in SOR-resistant HCC are analyzed, primarily including remodeling the tumor microenvironment (TME), restoring normal epigenetic regulation, improving drug metabolism, and inhibiting abnormally activated signaling molecules and pathways. Finally, the advantages and disadvantages of nanocomposites used to reverse drug resistance are discussed, and their development direction in future research is prospected, which provide new approaches for developing advanced nanocomposites to overcome SOR resistance.
Keywords: nanocomposites, nanoparticles, nanomedicine, hepatocellular carcinoma, sorafenib, drug resistance, drug delivery, combination therapies